Curated news and analysis on clinical trials, drug approvals, and medical research.
Johnson & Johnson is scheduled to release Q1 2026 earnings on April 14, with analysts forecasting $2.68 per share and $23.6 billion in revenue. The healthcare giant recently reported strong Q4 2025 results that beat estimates. The company maintains a 62-year dividend increase history with a 64% payout ratio.
Multiple therapeutic approaches targeting the APOE4 gene are advancing, including small molecule drugs, gene therapies, and repurposed medications. The APOE4 variant confers a 60% lifetime Alzheimer's risk and affects brain metabolism, increasing seizure susceptibility. Research shows blood pressure drug terazosin can reduce seizures in APOE4 models by boosting cellular energy production.
The cell surface markers detection market is projected to grow from $7.01 billion in 2026 to $13.33 billion by 2034, driven by increasing adoption of flow cytometry and applications in immunotherapy research. The market serves pharmaceutical, biotechnology, academic, and clinical research organizations through various workflow stages including sample preparation and cell analysis.
Dewpoint Therapeutics has initiated a Phase 1a/2a clinical trial for DPTX3186, a first-in-class therapy targeting biomolecular condensates in advanced solid tumors. The drug's development is based on foundational research from Whitehead Institute on cellular organization and gene regulation. The trial represents an early clinical evaluation of condensate-based therapeutics for cancer treatment.
Silo Pharma said the Japan Patent Office issued a Notice of Allowance for a patent application covering SPC-15, its intranasal PTSD therapeutic. The allowed application covers composition and method claims, with formal patent grant expected to follow.
President Donald Trump’s April 2, 2026 proclamation sets a 100% Section 232 tariff on certain patented pharmaceuticals and APIs from July 31, 2026. Generics, biosimilars and several specialty categories are exempt, while some companies can qualify for reduced or zero tariffs through onshoring or MFN pricing agreements.
A retrospective study of 692 matched HNSCC trials found that sponsor-driven decisions and poor recruitment were the leading causes of early termination. The analysis also identified enrollment, funding source, trial phase, and inclusion of procedures or surgery as factors associated with failure.
GC Biopharma said a review paper in Human Vaccines & Therapeutics analyzed more than 40 studies on its MAV/06 varicella vaccine strain. The paper summarized 30 years of data showing 99-100% neutralizing antibody rates and adverse event incidence of 0.41 to 0.57 cases per 100,000 doses.
Athletes at the Milano Cortina 2026 Olympic Winter Games span a wide age range, from teenagers to competitors in their 50s. Research suggests hormonal changes may affect bone health and stress-fracture risk more directly than athletic performance.
New data from 1,868 SEER-linked patients showed DecisionDx-Melanoma identified significant five-year survival differences within the same AJCC stage. The findings were presented at the 2026 AAD Annual Meeting.
A meta-analysis of 68 studies found patients with mental disorders consistently showed higher brain age than healthy controls. The largest effects were seen in schizophrenia spectrum and neurocognitive disorders.
The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.
JAMA Neurology published Phase 2b PARADIGM results for PrimeC in ALS, showing slower functional decline, fewer ALS-related complications and longer survival. NeuroSense is preparing a Phase 3 trial and received Brazilian patent protection through October 2042.
The microfluidics market is projected to grow from $10.33 billion in 2025 to $20.73 billion by 2030. Growth is tied to lab-on-a-chip research, miniaturized diagnostics, and pharmaceutical R&D adoption.
Organogenesis Holdings said first-quarter fiscal 2026 financial results will be reported after the market closes on May 7, followed by a 5:00 p.m. Eastern Time conference call.
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
NRx Pharmaceuticals said an FDA Type C meeting indicated a path to an NDA for NRX-100, using clinical trial results and real-world ketamine data from more than 65,000 patients.
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
Agios Pharmaceuticals said it will host a conference call and live webcast on April 29, 2026, at 8:00 a.m. ET to report first-quarter 2026 financial results and business highlights. The webcast and replay will be available on the Investors section of the company’s website.
Scinai acquired Recipharm Israel Ltd., added the Yavne cGMP manufacturing site to its CDMO platform, and entered a long-term commercial collaboration with Recipharm. The company later reorganized its CDMO activities into Scinai Biopharma Services and outlined a 2026 CDMO revenue target of about $5 million.
